![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Monday, October 26, 2009 11:38:39 AM
As the world population continues to grow and distances between people dwindle, a different kind of threat to personal safety, other than bullets, bombs, natural disasters or accidents, is much on the minds of our globally connected population: germs. More specifically, global pandemics of deadly germs.
According to the World Health Organization, nearly 36 thousand people in 76 countries have been infected with the H1N1 virus (Swine flu), causing 163 deaths. As fears that the virus may mutate to a more potent strain mount, the lesson is clear: more people plus more travel equals more germ transmission. While outbreaks of deadly diseases in the past (and present) such as Typhoid fever and influenza are horrific, humankind’s effort and scientific achievements in the name of combating such diseases are truly awe-inspiring.
One such innovator is Aethlon Medical, Inc. (OTC BB: AEMD), developer of the Hemopurifier®. The Hemopurifier is a patented extracorporeal device that captures circulating viruses and viral proteins and toxins before the occurrence of cell and organ infection. The filtration device has already seen significant results in the treatment of HIV, Hepatitus C, Marburg, Ebola, Measles, Mumps, influenza (including the strain of H1N1 that left 57 people dead in the U.S. earlier this year), and Orthopox virus. The Hemopurifier is classified as a broad-spectrum antiretroviral — broad-spectrum inhibitors are naturally occurring antiviral compounds occurring in certain kinds of mushrooms and fungi.
On May 5, 2009, Aethlon reported the following:
“[A]n HIV-infected individual, who received 12 Hemopurifier® treatments during the span of one month, had an average viral load reduction of 55% during each four-hour Hemopurifier® treatment. The study was conducted in the absence of any antiviral drug therapy. Based on this data, mathematical treatment models of approximately 1.5 days of continuous Hemopurifier® treatment would reduce patient viral load to undetectable levels.”
The problem with viral diseases, as anyone who has received a flu shot in the spring knows, is that they are continually evolving. The AIDS and HIV viruses are the most notorious cases of this, and their continually evolving resistance to treatment methods makes them among some of the deadliest in the world. Treatments for such viruses involve multiple-medication “cocktails” taken several times a day, and side effects can include nausea, diarrhea, malaise, and fatigue. Tantamount to finding effective treatments is the goal of finding treatments that improve the patient’s quality of life overall as well as reduce viral load in the bloodstream, as months of treatment can be physically, mentally and emotionally debilitating.
Aethlon’s Hemopurifier is remarkable not only because initial observations from the HIV study indicate the device could inhibit and reverse HIV disease progression in the absence of antiviral drugs but also because the same device may be usable for treating different viral diseases. Since the beginning of 2009, the Hemopurifier® has been demonstrated safe and effective in reducing patient viral load in both Hepatitis-C Virus (HCV) and Human Immunodeficiency Virus (HIV) infections. Aethlon believes the Hemopurifier® is the first therapeutic candidate to demonstrate viral reduction benefit against two different viral species in human studies.
James A. Joyce, Chairman and CEO of Aethlon, in his 2008 publication, The Broad-Spectrum Treatment of Biological Weapons and Emerging Pandemic Threats, writes:
“The advancement of single-target drug and vaccine therapies as the predominant strategy to address a universe of known and unknown bioterror and pandemic threats is clinically and economically unfeasible. Accordingly, the Department of Health and Human Services (HHS) of the United States has decreed that broad-spectrum therapies, able to demonstrate effectiveness in combating multiple pathogens, will become a focal point for government initiatives that encourage the development of countermeasures against bioterror and pandemic threats.”
Rather than focus efforts on combating a single virus, Aethlon’s more modern approach to combating such pandemics seems to be paying off. To date, the data further reinforces the company’s position of the Hemopurifier® as a leading broad-spectrum countermeasure against drug and vaccine resistant viruses. Truly remarkable.
Recent AEMD News
- Aethlon Medical to Release Fiscal Year End Financial Results and Host Conference Call on June 27, 2024 • PR Newswire (US) • 06/21/2024 12:01:00 PM
- Aethlon Medical Receives Ethics Committee Approval for Hemopurifier® Cancer Trial • PR Newswire (US) • 06/18/2024 12:01:00 PM
- Aethlon Medical Prepares for Potentially Transformative Phase 1 Cancer Treatment Studies • PR Newswire (US) • 06/03/2024 12:01:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/24/2024 05:24:31 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/17/2024 08:05:28 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 05/17/2024 04:15:21 AM
- Form 424B4 - Prospectus [Rule 424(b)(4)] • Edgar (US Regulatory) • 05/16/2024 08:05:23 PM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 05/15/2024 01:27:15 PM
- Aethlon Medical Announces Pricing of $4.7 Million Public Offering • PR Newswire (US) • 05/15/2024 01:15:00 PM
- Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 05/13/2024 09:30:18 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/10/2024 12:01:40 PM
- Aethlon Medical Reports Positive Results From an In Vitro Binding Study of Its Hemopurifier® in Removing Extracellular Vesicles From Cancer Patient Plasma • PR Newswire (US) • 05/10/2024 12:01:00 PM
- Aethlon Medical Enters Into Materials Transfer Agreement for Santersus AG's NucleoCapture and HemoNucleoCapture Devices • PR Newswire (US) • 02/21/2024 01:01:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/14/2024 10:15:40 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/14/2024 09:15:41 PM
- Aethlon Medical Announces Fiscal Third Quarter Financial Results and Provides Corporate Update • PR Newswire (US) • 02/14/2024 09:15:00 PM
- Aethlon Medical to Release Fiscal Third Quarter Financial Results and Host Conference Call on February 14, 2024 • PR Newswire (US) • 02/07/2024 01:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/02/2024 11:06:06 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/02/2024 11:04:32 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/02/2024 11:02:52 PM
- Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 12/22/2023 09:01:12 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/27/2023 12:49:31 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/14/2023 09:15:39 PM
Bantec's Howco Short Term Department of Defense Contract Wins Will Exceed $1,100,000 for the current Quarter • BANT • Jun 25, 2024 10:00 AM
ECGI Holdings Targets $9.7 Billion Equestrian Apparel Market with Allon Brand Launch • ECGI • Jun 25, 2024 8:36 AM
Avant Technologies Addresses Progress on AI Supercomputer-Driven Data Centers • AVAI • Jun 25, 2024 8:00 AM
Green Leaf Innovations, Inc. Expands International Presence with New Partnership in Dubai • GRLF • Jun 24, 2024 8:30 AM
Bemax Inc. Positions to Capitalize on Industry Growth with New Improved Quality of Mother's Touch® Disposable Diapers • BMXC • Jun 24, 2024 8:00 AM
Last Shot Hydration Drink Announced as Official Sponsor of Red River Athletic Conference • EQLB • Jun 20, 2024 2:38 PM